A Study With CIT-013 in RA Patients

Study acronym: Citydream
StatusCompleted
PhasePhase 2
SponsorCitryll BV
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Trial sites reduced: 24 → 20 locations
    • Primary completion date changed from estimate of Apr 2027 to Jul 2, 2026
    • Enrollment target: estimated 88 to confirmed 96
    • Study completion date changed from estimate of Jul 2027 to Aug 11, 2026
    • Eligibility criteria expanded, about 14 words
  2. Site details revised at 6 of 24 sitesv11
  3. Study sites: 23 to 24v10
  4. Site details revised at 4 of 23 sitesv9
  5. Study sites: 20 to 23
    • Eligibility criteria expanded, about 2 words
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary endpoint revised
    • Site details revised at 6 of 20 sites
    v7
  2. Start date changed from estimate of Aug 2025 to Jul 29, 2025v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 20 of 20 sites
    v5
  4. Study sites: 5 to 20v4
  5. Enrollment target: 77 to 88
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 1 of 2 entries
    v3
  6. Enrollment target: 150 to 77v2 Show 5 more changesShow less
    • Start date: Nov 2024 to Aug 2025
    • Study sites: 7 to 5
    • Interventions: CIT-013 high dose (Drug), CIT-013 low dose (Drug), Placebo (Drug) to CIT-013 high dose (Drug), CIT-013 low dose (Drug), CIT-013 medium dose (Drug), Placebo (Drug)
    • Eligibility criteria revised
    • Study arms: 3 to 4
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA. Participants will: Take receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
Trial Details
NCT Number NCT06567470
Lead Sponsor Citryll BV
Conditions
(from sponsor)		 Rheumatoid Arthritis
Related terms Arthritis, Rheumatoid
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov